Nitrous Oxide for Pain Management During In-office Transcervical Sterilization

NCT ID: NCT02312739

Last Updated: 2016-07-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2015-03-31

Brief Summary

This is a randomized, double blind study that aims to measure the difference in maximum pain experienced during in-office transcervical sterilization (Essure®) for women receiving either inhaled nitrous oxide or standard oral analgesia (Vicodin and Lorazepam) with inhaled oxygen.

The investigators hypothesize that inhaled nitrous oxide will reduce the pain experienced more than standard oral medications in women undergoing in-office transcervical sterilization.

Detailed Description

Hysteroscopic permanent sterilization with Essure® is increasingly performed in the outpatient setting. No optimal outpatient analgesia regimen has been identified for the Essure® procedure. The investigators propose a study of inhaled nitrous oxide administered with oxygen, hereafter referred to as nitrous oxide (NO), as an intervention to lower pain experienced during the in-office procedure. The investigators hypothesize that, compared to standard oral medications, inhaled NO will decrease patient anxiety associated with the in-office procedure, as well as increase patient satisfaction and provider perceived ease of device insertion.

Women presenting to the clinic for family planning will receive our standard counseling on all forms of contraception, including short and long acting reversible contraception, and methods for permanent sterilization. Once the patient decides to have a sterilization procedure with the transcervical approach (Essure® procedure), she will undergo the standard pre-procedure evaluation, which includes a complete history, appropriate physical examination including pelvic examination, and urine pregnancy test.

Eligible women interested in sterilization will be advised of the study as an investigation evaluating nitrous oxide as an alternative to our current oral sedation pain management for in-office procedures. If they choose hysteroscopic sterilization, they will undergo informed consent for the Essure® procedure. Providers will assess patient eligibility criteria for possible enrollment into the study. If patients are eligible and choose to participate in the research study, consent for participation will be obtained. At this time patients will be randomized to treatment group based on a predetermined randomization scheme. For this research study comparing the use of NO versus oral pain medications, the NO group will receive two placebo pills and the standard group will receive one 5/325 mg oral tablet of Vicodin and one 1 mg oral tablet of lorazepam 30 minutes prior to the procedure. The standard care group will receive oxygen (instead of NO) during the procedure. All participants will receive 30 mg of intramuscular ketorolac 30 minutes prior to the procedure.

NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention. NO can be titrated up to a concentration of 70% nitrous oxide and 30% oxygen based on desired analgesic effects per a predetermined sedation scale as part of the University of New Mexico Center for Reproductive Health (UNM CRH) nitrous administration protocol. All patients will be monitored with a pulse-oximeter. The patient will be fitted to their mask once the procedure is ready to begin. A single nurse will administer nitrous oxide and oxygen for all procedures. Every study patient will receive a minimum of 3 minutes of oxygen at the end of the procedure to minimize the side effects of NO. Additional oxygen will be administered as needed if a patient is experiencing residual effects of NO.

Prior to the procedure and study medications, patients will complete patient information and demographics questionnaire and will receive instruction on the 0-100mm visual analogue scale (VAS) and Spielberger State-Trait Anxiety Inventory (STAI). A baseline pain score will be recorded using the 0-100mm VAS with anchors 0 equals no pain and 100 equals worst pain imaginable, as well as baseline anxiety level using the STAI. At placement of the paracervical block and deployment of the second device coil, pain will be assessed again with the same 0-100mm VAS. At 3 to 5 minutes following completion of the procedure, maximal pain experienced during transcervical sterilization will be assessed by the patient. Prior to discharge from the clinic, the patient will rate her pain level using the same 0-100mm VAS, rate her level of anxiety with the procedure using the same STAI, and rate her overall satisfaction with the procedure measured using a 5-point Likert scale.

Immediately after the procedure, the physician will complete a 0-100mm VAS on ease of insertion of the sterilization devices with anchors 0 equals no difficulty and 100 equals very difficult. The physician will also complete a 0-100mm VAS on hysteroscopic procedure difficulty with anchors 0 equals no difficulty and 100 equals very difficult.

The standard transcervical sterilization procedure is not being evaluated in this study. After patients complete the procedure, they are contacted approximately 75 days from the procedure date to schedule a confirmatory test, hysterosalpingogram, which is required at 90 days to demonstrate successful sterilization.

Conditions

Contraception; Inhalation of Nitrous Oxide

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Vicodin, Lorazepam and Oxygen

Patients in this group will receive the Standard Oral Pain Medications consisting of Vicodin and Lorazepam, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Oxygen via scented mask will also given.

All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique.

Group Type: ACTIVE_COMPARATOR

In-office Transcervical Sterilization (Essure®)

Intervention Type: PROCEDURE

The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.

Standard Oral pain medications

Intervention Type: DRUG

one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure

Intramuscular Ketorolac

Intervention Type: DRUG

30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure

Oxygen

Intervention Type: OTHER

Oxygen at 5L/min given to patients randomized to the active comparator arm

Placebo pills and Nitrous Oxide

Patients in this group will receive two placebo pills, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Nitrous oxide will be administered during the procedure via scented mask.

All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique.

Group Type: EXPERIMENTAL

In-office Transcervical Sterilization (Essure®)

Intervention Type: PROCEDURE

The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.

Intramuscular Ketorolac

Intervention Type: DRUG

30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure

Placebo pills

Intervention Type: DRUG

Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure

Nitrous Oxide

Intervention Type: OTHER

Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm

Interventions

In-office Transcervical Sterilization (Essure®)

The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.

Intervention Type: PROCEDURE

Standard Oral pain medications

one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure

Intervention Type: DRUG

Intramuscular Ketorolac

30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure

Intervention Type: DRUG

Placebo pills

Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure

Intervention Type: DRUG

Oxygen

Oxygen at 5L/min given to patients randomized to the active comparator arm

Intervention Type: OTHER

Nitrous Oxide

Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm

Intervention Type: OTHER

Other Intervention Names

Essure®; Non-surgical permanent birth control; Transcervical sterilization; Hysteroscopic sterilization; Vicodin; Lorazepam; IM ketorolac; Placebo; O2

Eligibility Criteria

Inclusion Criteria

• Premenopausal women desiring permanent sterilization and have chosen to proceed with a transcervical sterilization approach
• Speaks English or Spanish
• If relying on state or federal funding for sterilization, must have appropriate federal consents signed 30 days prior to the sterilization procedure
• Agrees to either a hormonal endometrial preparation prior to the procedure or schedule the procedure during the follicular phase (days 5 through 12) of their menstrual cycle
• Sexually active who agrees to contraception for 3 months post procedure, including condoms, followed by a hysterosalpingogram (HSG) for confirmation of fallopian tubal occlusion.

Exclusion Criteria

• With contraindications for nitrous oxide including: respiratory infection, chronic obstructive pulmonary disease (COPD), intoxication or use of street drugs, inability to breathe through their nose.
• Have taken narcotic pain medications prior to coming to their appointment
• Unsure about desire to end fertility
• History of pelvic inflammatory disease in the past 3 months
• Pregnancy or suspicion of pregnancy
• Delivery or termination of a pregnancy within the last 6 weeks
• Known allergy to contrast
• Uterine anomalies
• Previous tubal surgery
• Cervical or endometrial cancer
• Allergy to Vicodin, lorazepam, or lidocaine.

• Minimum Eligible Age: 21 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Society of Family Planning

OTHER

Sponsor Role: collaborator

Bayer

INDUSTRY

Sponsor Role: collaborator

University of New Mexico

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rameet Singh, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

UNM OB GYN Division of Family Planning

Locations

UNM Center for Reproductive Health

Albuquerque, New Mexico, United States

Countries

United States

Other Identifiers

UNMHSC13-594

Identifier Type: -

Identifier Source: org_study_id